Inovio Pharmaceuticals

Ology Bioservices, Inovio Partner To Manufacture COVID-19 DNA Vaccine With $11.9 Million Department of Defense Grant

Retrieved on: 
Tuesday, March 24, 2020
Science, Biotechnology, Defense, Research, Pharmaceutical, Contracts, Health, Infectious diseases, Vaccination, Vaccine, Virology, DNA vaccination, Ology, Branches of biology, Biology, Ology Bioservices Inc., Inovio Pharmaceuticals, the JPEO-CBRND

Under this program, Ology Bioservices will work with Inovio Pharmaceuticals to manufacture Inovios DNA vaccine (INO-4800) for prevention of infection with the COVID-19 virus.

Key Points: 
  • Under this program, Ology Bioservices will work with Inovio Pharmaceuticals to manufacture Inovios DNA vaccine (INO-4800) for prevention of infection with the COVID-19 virus.
  • The aim of the program is to rapidly and efficiently deliver the vaccine to the Department of Defense for upcoming clinical trials.
  • Peter H. Khoury, Ph.D., President and Chief Executive Officer of Ology Bioservices, noted, We are excited to be working with the Department of Defense and Inovio to rapidly respond to this crisis.
  • Powered by the U.S. Department of Defense support, Inovio is pleased to partner with Ology to enable rapid response manufacture of INO-4800 especially for the nations warfighters and other military personnel.